AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 182 min read$RDNT

Wesdorp Cornelis sold $276K of RDNT

Wesdorp Cornelis (Pres & CEO, Digital Health) sold 4,750 shares of RadNet, Inc. (RDNT) at $58.11 ($0.28M total) on 2026-06-16.

Original reporting
SEC EDGAR · Wesdorp Cornelis
Published Jun 18, 2026, 10:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$RDNT
Neutral
high confidence
Mentioned
$RDNT
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RDNTNeutralLow
01

Why it matters

This provides a concrete datapoint on CEO selling size, price, and post-transaction holdings, but it does not introduce new operational or financial guidance.

02

Market read

Useful for monitoring insider behavior, but unlikely to drive a fundamental repricing on its own.

03

What to watch

Insider sales are common and often non-informational; traders should compare with prior insider activity and whether other executives/large holders are also selling or buying around the same period.

Relevance 4/10Novelty 5/10Timing: Filed after-hours on 2026-06-18; reflects sale executed 2026-06-16.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for RadNet, Inc. (RDNT).

Company-level read

Ticker impact

$RDNTNeutralHigh confidence
Context

RadNet CEO Wesdorp Cornelis filed a Form 4 selling 4,750 shares at $58.11 on 2026-06-16 for ~$276K.

Expected impact

Likely limited near-term impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

The filing is a disclosed sale with no 10b5-1 plan and no accompanying fundamental catalyst (no guidance, deal, or regulatory action).

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide datapoint.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a stated 10b5-1 plan could be misread as bearish; the sale may be for diversification/taxes rather than a view on fundamentals.

Key entities

  • US-listed issuer
    RadNet, Inc.

    Subject of the Form 4 insider sale by its CEO.

  • Insider
    Wesdorp Cornelis

    President & CEO, Digital Health; reported an open-market sale of RDNT shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RDNT insider trading history →

Related articles

AUG 11
$ABXMed

Barrick Profit Soars, Nvidia Eyes $500B AI Push, M&A Accelerates

The article reports multiple US corporate updates. Barrick Mining said Q2 profit rose 50% to $1.22B, with revenue up 44% to $5.29B, and agreed with Newmont on a $1.95B cash top-up to expand Nevada Gold Mines. Nvidia is working on a $500B AI financing venture; Intel announced a $15B stock offering. It also covers results for Axsome (revenue +46%), Monday.com, RadNet, NESR, and Camtek.

hdfcsky.com7 min
AUG 10
$RDNTHigh

RadNet, Inc. (RDNT): Results of Operations and Financial Condition

RadNet, Inc. (RDNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA (1) and Revises Upwards 2026 Financial Guidance Ranges · Total Company Revenue increased 25.0% to a quarterly record of $622.7 million in the secon

SEC EDGAR 8-K6 min
JUN 25
$RDNTMed

DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite

DeepHealth, a RadNet subsidiary (NASDAQ: RDNT), said it received two FDA 510(k) clearances for its Breast Suite: Breast Arterial Calcification (BAC) Assessment and prior-exam integration into ProFound Pro, to be marketed as Mammo Dx. Both are now commercially available in the U.S. DeepHealth reported BAC performance of >90% sensitivity and >88% specificity.

manilatimes.net5 min